

Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and Forecast, 2018-2028

<https://marketpublishers.com/r/GBF785346260EN.html>

Date: February 2019

Pages: 191

Price: US\$ 5,000.00 (Single User License)

ID: GBF785346260EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Global Scenario

The healthcare industry is a multi-billion-dollar market consisting of various verticals aimed at improving patient lives. The industry has experienced considerable advancement in terms of diagnosis and treatment, yet cancer remains as one of the leading causes of death. Cancer acts as one of the major issues of the global healthcare industry, as it is the second leading cause of death all around the world (according to WHO). The effects of cancer have had a major impact on society across the world and currently accounts for almost 70% of death in low- and middle-income countries. As per GLOBOCAN data, there were almost 14 million cancer cases globally in 2012, which claimed almost 8 million patient lives. As a result, significant scientific innovation is taking place in the field of oncology for the development of novel oncology medicines that are significantly propelling the growth of cancer treatment market.

Immunotherapy is a Type of Personalized Medicine

Cancer immunotherapy or, immuno-oncology, is the treatment that utilises the body's own immune system to combat cancer. These immunotherapy treatments either boost the body's immune system or may act on immune system to identify and destroy the cancerous cells. Immunotherapy is a type of personalized medicine that works better for certain types of cancer. Globally, patients are displaying a positive response towards

advanced cancer therapy drugs which effectively help manage and treat their medical conditions. This, in turn, is gradually increasing the adoption rate of the cancer immunotherapy drugs.

Scope of Cancer Immunotherapy Market Report

The cancer immunotherapy market consists of products such as monoclonal antibodies, check point inhibitors, cancer vaccines and other medicinal treatments such as adoptive cell therapies and oncolytic viral therapies used in the treatment of cancer. The market analysis report includes an in-depth examination of the key ecosystem players, key strategies, and developments taking place in this market.

The purpose of the study is to gain a holistic view of the global cancer immunotherapy market in terms of various factors influencing the same, such as key market trends, competitive and regulatory aspects of the market, scientific innovations in the oncology field, etc. The scope of the report is centred upon conducting a detailed study of the solutions allied with cancer immunotherapy market, which involves drugs used in different therapeutic applications of cancer treatment.

Market Dynamics (Market Drivers, Threats, Opportunities) and Market Segmentation

Additionally, it includes market dynamics (market drivers, opportunities, and challenges) and industry analysis. The market has been classified based on different therapeutic indications, such as breast cancer, melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, gastric cancer, and others. Geographically, the market can be segmented into five distinct regions including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.

The global cancer immunotherapy market is segmented into three different parts: 'by products', 'by therapeutic indication', and 'by region'. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The market by region has

been further sub-segmented in various countries, and in each sub-segment the key market trends, list of the key players, and recent developments, have been discussed.

The answers to the following key questions can be derived from this report:

What is cancer immunotherapy? What are the products included in immunotherapy?

What are the major market drivers, restraints, and opportunities in the global cancer immunotherapy market?

What were the market shares of the leading segments, and sub-segments of the global cancer immunotherapy market in 2017 and what will be its share in 2028?

How will each segment of the global cancer immunotherapy market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?

What are the influencing factors that may affect the market share of the key players?

What are the key developmental strategies implemented by the key players to stand out in this market?

What are the major regulatory authorities/ associations/ consortiums affecting the cancer immunotherapy market and what are the main designations facilitating development and approval of cancer drugs?

Which product segment is expected to register the highest CAGR for the global cancer immunotherapy market?

How has the market been segmented based on therapeutic indication? Which therapeutic indication segment had the largest share, and the fastest growth rate in the global cancer immunotherapy market?

Which geographical region will contribute to the highest sales of the cancer immunotherapy drugs during the forecast period and which will have the highest CAGR?

What are major companies developing cancer immunotherapy drugs targeted for different therapeutic indication?

Key Players

The key players that have been contributing significantly in the cancer immunotherapy market include Aduro Biotech, Inc., Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Gilead Sciences, Inc., among others.

Contents

EXECUTIVE SUMMARY

1 MARKET OVERVIEW

- 1.1 Cancer Immunotherapy
- 1.2 Types of Cancer Immunotherapy

2 MARKET DYNAMICS

- 2.1 Drivers
 - 2.1.1 Rising Prevalence of Cancer
 - 2.1.2 Unmet Medical Needs of Cancer Patients
 - 2.1.3 Rising R&D Expenditure in the Immuno-Oncology Segment
 - 2.1.4 Advancement of Precision Medicine in Immuno-oncology
- 2.2 Restraints
 - 2.2.1 High Cost of Treatment
 - 2.2.2 Adverse Effects of Immunotherapy Treatment
- 2.3 Opportunities
 - 2.3.1 Development of Targeted Therapy
 - 2.3.2 Development of Healthcare Infrastructure and Reimbursement Policies in Emerging Economies
 - 2.3.3 Combination Therapy

3 COMPETITIVE LANDSCAPE

- 3.1 Key Developmental Strategies
 - 3.1.1 Product Approval
 - 3.1.2 Agreements, Collaborations and Partnerships
 - 3.1.3 Clinical Study
 - 3.1.4 Regulatory Designation
 - 3.1.5 Acquisition
 - 3.1.6 Others
- 3.2 Market Share Analysis

4 INDUSTRY INSIGHTS

- 4.1 Regulatory Organizations/ Associations/ Consortia

4.2 Patent Landscape

4.3 Regulatory Designations

5 GLOBAL CANCER IMMUNOTHERAPY MARKET (BY PRODUCT)

5.1 Monoclonal Antibodies

5.2 Checkpoint Inhibitors

5.2.1 CTLA-4 Inhibitors

5.2.2 PD-L1 Inhibitors/ PD-1 Inhibitors

5.3 Cancer Vaccines

5.3.1 Other Cancer Therapies

5.3.1.1 Oncolytic Viruses

5.3.1.2 Adoptive Cell Transfer

6 GLOBAL CANCER IMMUNOTHERAPY MARKET (BY THERAPEUTIC INDICATION)

6.1 Breast Cancer

6.2 Non-Small Cell Lung Cancer (NSCLC)

6.3 Melanoma

6.4 Colorectal Cancer

6.5 Renal Cell Carcinoma

6.6 Gastric Cancer

6.7 Others

7 GLOBAL CANCER IMMUNOTHERAPY MARKET (BY REGION)

7.1 North America

7.1.1 The U.S.

7.1.2 Canada

7.2 Europe

7.2.1 Germany

7.2.2 The U.K.

7.2.3 France

7.2.4 Spain

7.2.5 Italy

7.2.6 Russia

7.2.7 Poland

7.2.8 Austria

- 7.2.9 Switzerland
- 7.2.10 Belgium
- 7.2.11 The Netherlands
- 7.2.12 Sweden
- 7.2.13 Finland
- 7.2.14 Denmark
- 7.2.15 Ireland
- 7.2.16 Rest-of-Europe
- 7.3 Asia-Pacific
 - 7.3.1 China
 - 7.3.2 Japan
 - 7.3.3 India
 - 7.3.4 Australia
 - 7.3.5 South Korea
 - 7.3.6 New Zealand
 - 7.3.7 Malaysia
 - 7.3.8 Bangladesh
 - 7.3.9 Rest-of-Asia-Pacific
- 7.4 Latin America
 - 7.4.1 Brazil
 - 7.4.2 Mexico
 - 7.4.3 Argentina
 - 7.4.4 Rest-of-Latin-America
- 7.5 Rest-of-the-World (RoW)
 - 7.5.1 Saudi Arabia
 - 7.5.2 The U.A.E.
 - 7.5.3 South Africa
 - 7.5.4 Israel
 - 7.5.5 Others

8 COMPANY PROFILES

- 8.1 Overview
- 8.2 Aduro Biotech
 - 8.2.1 Company Overview
 - 8.2.2 Role of Aduro Biotech in Cancer Immunotherapy Market
 - 8.2.3 Financials
 - 8.2.4 Key Insights about the Financial Health of the Company
 - 8.2.5 SWOT Analysis

8.3 Amgen

8.3.1 Company Overview

8.3.2 Role of Amgen Inc in the Cancer Immunotherapy Market

8.3.3 Financials

8.3.4 Key Insights about Financial Health of the Company

8.3.5 SWOT Analysis

8.4 AstraZeneca PLC

8.4.1 Company Overview

8.4.2 Role of AstraZeneca in Cancer Immunotherapy Market

8.4.3 Financials

8.4.4 Key Insights about Financial Health of the Company

8.4.5 SWOT Analysis

8.5 Bristol-Myers Squibb

8.5.1 Company Overview

8.5.2 Role of Bristol-Myers Squibb in the Cancer Immunotherapy Market

8.5.3 Financials

8.5.4 Key Insights about Financial Health of the Company

8.5.5 SWOT Analysis

8.6 Celgene Corporation

8.6.1 Company Overview

8.6.2 Role of Celgene Corporation in Cancer Immunotherapy Market

8.6.3 Financials

8.6.4 Key Insights about Financial Health of the Company

8.6.5 SWOT Analysis

8.7 DNAtrix Therapeutics

8.7.1 Company Overview

8.7.2 Role of DNAtrix Therapeutics in Cancer Immunotherapy Market

8.7.3 SWOT Analysis

8.8 Eli Lilly and Company

8.8.1 Company Overview

8.8.2 Role of Eli Lilly and Company in Cancer Immunotherapy Market

8.8.3 Financials

8.8.4 Key Insights about Financial Health of the Company

8.8.5 SWOT Analysis

8.9 Gilead Sciences, Inc.

8.9.1 Company Overview

8.9.2 Role of Gilead Sciences, Inc. in Cancer Immunotherapy Market

8.9.3 Financials

8.9.4 Key Insights About the Financial Health of the Company

- 8.9.5 SWOT Analysis
- 8.10 Fate Therapeutics
 - 8.10.1 Company Overview
 - 8.10.2 Role of Fate Therapeutics in cancer immunotherapy market
 - 8.10.3 Financials
 - 8.10.4 Key Insights about the Financial Health of the Company
 - 8.10.5 SWOT Analysis
- 8.11 F. Hoffmann La Roche
 - 8.11.1 Company Overview
 - 8.11.2 Role of F. Hoffmann La Roche in Cancer Immunotherapy market
 - 8.11.3 Financials
 - 8.11.4 Key Insights About the Financial Health of the Company
 - 8.11.5 SWOT Analysis
- 8.12 JOHNSON & JOHNSON
 - 8.12.1 Company Overview
 - 8.12.2 Role of Johnson & Johnson in Cancer Immunotherapy Market
 - 8.12.3 Financials
 - 8.12.4 Key Insights about the Financial Health of the Company
 - 8.12.5 SWOT Analysis
- 8.13 Merck & Co., Inc.
 - 8.13.1 Company Overview
 - 8.13.2 Role of Merck & Co, Inc. in Cancer Immunotherapy Market
 - 8.13.3 Financials
 - 8.13.4 Key Insights about the Financial Health of Company
 - 8.13.5 SWOT Analysis
- 8.14 Novartis AG
 - 8.14.1 Company Overview
 - 8.14.2 Role of Novartis AG in Cancer Immunotherapy Market
 - 8.14.3 Financials
 - 8.14.4 Key Insights about the Financial Health of Company
 - 8.14.5 SWOT Analysis
- 8.15 Pfizer, Inc.
 - 8.15.1 Company Overview
 - 8.15.2 Role of Pfizer, Inc. in Cancer Immunotherapy Market
 - 8.15.3 Financials
 - 8.15.4 Key Insights about the Financial Health of the Company
 - 8.15.5 SWOT Analysis
- 8.16 Precision BioSciences, Inc.
 - 8.16.1 Company Overview

8.16.2 Role of Precision BioSciences, Inc. in Cancer Immunotherapy Market

8.16.3 SWOT Analysis

8.17 IOVANCE BIOTHERAPEUTICS, INC.: Snapshot

8.17.1 Company Overview

8.17.2 Role of IOVANCE BIOTHERAPEUTICS, INC. in cancer immunotherapy market

9 RESEARCH SCOPE AND METHODOLOGY

9.1 Scope of the Report

9.2 Global Cancer Immunotherapy Market Segmentation

9.3 Research Methodology

9.3.1 Primary Research

9.3.2 Secondary Research

9.3.3 Key Data Points from Primary and Secondary Sources

9.3.4 Data Triangulation

9.3.5 Top-Down Approach

9.3.6 Bottom- Up Approach

9.4 Assumptions and Limitations

List Of Tables

LIST OF TABLES

Table 1: Total Regional Geriatric Population (%), 2015 and 2030

Table 2: Impact analysis of Market Drivers

Table 3: Impact Analysis of Market Restraints

Table 1.1: Estimated New Cases and Estimated Deaths in 2018 as per American Cancer Society

Table 2.1: R&D Expense of Major Companies

Table 3.1: Key Company Acquisitions, 2015-2018

Table 4.1: Regulatory Organizations/ Associations.

Table 4.2: Important Regulatory Designations

Table 5.1: List of Monoclonal Antibodies Used in Immunotherapy

Table 5.2: PD-L1 Inhibitors and Their FDA Approved Indication

Table 5.3: PD-1 Inhibitors and Their FDA Approved Indication

Table 6.1: Estimated Incidence, Mortality and Prevalence of Breast Cancer in 2012 (Numbers in thousands)

Table 6.2: Top 25 countries with the highest rates of breast cancer in 2018:

Table 6.3: Estimated Incidence, Mortality, and Prevalence of Lung Cancer (for both sexes) in 2012 (Numbers in thousands)

Table 6.4: NSCLC: 5-Year Survival Rate by Stage

Table 6.5: Age Standardized rate of Colorectal cancer in 2018

Table 6.6: Estimated Incidence, Mortality, and Prevalence of Different Cancer (for both sexes) Worldwide in 2012

Table 6.7: Cervical Cancer Rates: Top 20 Countries in 2018

Table 6.8: Leukaemia: Top 10 Countries with Incidence Rates

Table 7.1: The U.S. Estimated Age-Standardized Incidence Rates in 2018

Table 7.2: Canada Estimated Age-Standardized Incidence Rates in 2018

Table 7.3: Germany Estimated Age-Standardized Incidence Rates in 2018

Table 7.4: The U.K. Estimated Age-Standardized Incidence Rates in 2018

Table 7.5: China Estimated Age-Standardized Incidence Rates in 2018

Table 7.6: Japan Estimated Age-Standardized Incidence Rates in 2018

Table 7.7: India Estimated Age-Standardized Incidence Rates in 2018

Table 7.8: Australia Estimated Age-Standardized Incidence Rates in 2018

Table 7.9: Brazil Estimated Age-Standardized Incidence Rates in 2018

Table 7.10: Mexico Estimated Age-Standardized Incidence Rates in 2018

Table 7.11: Argentina Estimated Age-Standardized Incidence Rates in 2018

Table 8.1: Aduro Biotech: Pipeline Products

Table 8.2: Celgene Product Pipeline

Table 8.3: DNAtrix Therapeutics: Pipeline Products

Table 8.4: Fate Therapeutics: Pipeline Products

List Of Figures

LIST OF FIGURES

- Figure 1: Global Cancer Immunotherapy Market, 2017 and 2028
- Figure 2: Global Cancer Immunotherapy Market (by Region), 2017 and 2028
- Figure 3: Global Cancer Immunotherapy Market (by Product), 2017 and 2028
- Figure 4: Global Cancer Immunotherapy Market (by Therapeutic Indication), 2017 and 2028
- Figure 5: Global Cancer Immunotherapy Market (by Region), 2017 and 2028
- Figure 1.1: Treatment for Cancer
- Figure 1.2: Global Cancer Immunotherapy Market, 2017-2028 (\$Billion)
- Figure 1.3: Key Players Involved in Cancer Immunotherapy
- Figure 2.1: Market Dynamics
- Figure 3.1: Share of Key Developmental Strategies, 2015-2018
- Figure 3.2: Product Approvals, (by Company), 2015-2018
- Figure 3.3: Agreements, Collaborations and Partnerships, (by Company), 2015-2018
- Figure 3.4: Clinical Study, (by Company), 2015-2018
- Figure 3.5: Regulatory Designations, (by Company), 2015-2018
- Figure 3.6: Other Strategies (by Company), 2015-2018
- Figure 3.7: Market Share Analysis, 2017 and 2018
- Figure 4.1: Share of Patents by Ownership, 2015-2018
- Figure 5.1: Global Monoclonal Antibodies Market, 2017-2028
- Figure 5.2: Global Checkpoint Inhibitors Market, 2017-2028
- Figure 5.3: Global Cancer Vaccine Market, 2017-2028
- Figure 5.4: Development of CAR-T Therapy
- Figure 5.5: Global Cancer Immunotherapy Market for Other Products, 2017-2028
- Figure 6.1: Types of Therapeutic Cancer Indications
- Figure 6.2: Global Breast Cancer Immunotherapy Market, 2017-2028
- Figure 6.3: Global NSCLC Immunotherapy Market, 2017-2028
- Figure 6.4: Global Melanoma Immunotherapy Market, 2017-2028
- Figure 6.5: Global Colorectal Cancer Immunotherapy Market, 2017-2028
- Figure 6.6: Global Renal Cell Carcinoma Immunotherapy Market, 2017-2028
- Figure 6.7: Global Gastric Cancer Immunotherapy Market, 2017-2028
- Figure 6.8: Global Cancer Immunotherapy Market for Other Cancer Indications, 2017-2028
- Figure 7.1: Global Cancer Immunotherapy (by Region)
- Figure 7.2: Global Cancer Immunotherapy Market (by Region), 2017-2028
- Figure 7.3: North America Cancer Immunotherapy Market

- Figure 7.4: North America Cancer Immunotherapy Market, by Country
- Figure 7.5: The U.S. Cancer Immunotherapy Market, 2017-2028
- Figure 7.6: Canada Cancer Immunotherapy Market
- Figure 7.7: Europe Cancer Immunotherapy Market
- Figure 7.8: Germany Cancer Immunotherapy Market, 2017-2028
- Figure 7.9: The U.K. Cancer Immunotherapy Market, 2017-2028
- Figure 7.10: France Cancer Immunotherapy Market, 2017-2028
- Figure 7.11: Spain Cancer Immunotherapy Market, 2017-2028
- Figure 7.12: Italy Cancer Immunotherapy Market, 2018-2028
- Figure 7.13: Russia Cancer Immunotherapy Market, 2018-2028
- Figure 7.14: Poland Cancer Immunotherapy Market, 2018-2028
- Figure 7.15: Austria Cancer Immunotherapy Market, 2018-2028
- Figure 7.16: Switzerland Cancer Immunotherapy Market, 2018-2028
- Figure 7.17: Belgium Cancer Immunotherapy Market, 2018-2028
- Figure 7.18: The Netherlands Cancer Immunotherapy Market, 2018-2028
- Figure 7.19: Sweden Cancer Immunotherapy Market, 2018-2028
- Figure 7.20: Finland Cancer Immunotherapy Market, 2018-2028
- Figure 7.21: Denmark Cancer Immunotherapy Market, 2018-2028
- Figure 7.22: Ireland Cancer Immunotherapy Market, 2018-2028
- Figure 7.23: Rest-of-Europe Cancer Immunotherapy Market, 2018-2028
- Figure 7.24: Asia-Pacific Cancer Immunotherapy Market, 2017-2028
- Figure 7.25: China Cancer Immunotherapy Market, 2017-2028
- Figure 7.26: Japan Cancer Immunotherapy Market, 2017-2028
- Figure 7.27: India Cancer Immunotherapy Market, 2017-2028
- Figure 7.28: Australia Cancer Immunotherapy Market, 2017-2028
- Figure 7.29: S. Korea Cancer Immunotherapy Market, 2017-2028
- Figure 7.30: New Zealand Cancer Immunotherapy Market, 2017-2028
- Figure 7.31: Malaysia Cancer Immunotherapy Market, 2017-2028
- Figure 7.32: Bangladesh Cancer Immunotherapy Market, 2017-2028
- Figure 7.33: Rest-of-Asia-Pacific Cancer Immunotherapy Market, 2017-2028
- Figure 7.34: Latin America Cancer Immunotherapy Market, 2017-2028
- Figure 7.35: Latin America Cancer Immunotherapy Market (by Country), 2017-2028
- Figure 7.36: Brazil Cancer Immunotherapy Market, 2017-2028
- Figure 7.37: Mexico Cancer Immunotherapy Market, 2017-2028
- Figure 7.38: Argentina Cancer Immunotherapy Market, 2017-2028
- Figure 7.39: Rest-of-Latin-America Cancer Immunotherapy Market, 2017-2028
- Figure 7.40: Saudi Arabia Cancer Immunotherapy Market, 2017-2028
- Figure 7.41: The U.A.E. Cancer Immunotherapy Market, 2017-2028
- Figure 7.42: South Africa Cancer Immunotherapy Market, 2017-2028

- Figure 7.43: Israel Cancer Immunotherapy Market, 2017-2028
- Figure 7.44: Others Cancer Immunotherapy Market, 2017-2028
- Figure 8.1: Aduro Biotech: Overall Financials, 2015-2017
- Figure 8.2: Aduro Biotech: Research and Development Expense, 2015-2017
- Figure 8.3: Aduro Biotech: SWOT Analysis
- Figure 8.4: Amgen Inc: Cancer Immunotherapy Product Portfolio
- Figure 8.5: Amgen Inc.: Overall Financials
- Figure 8.6: Amgen Inc.: Net Revenue (by Region), 2015-2017
- Figure 8.7: Amgen Inc.: R&D Expenditure, 2015-2017
- Figure 8.8: Amgen Inc.: SWOT Analysis
- Figure 8.9: AstraZeneca PLC: Cancer Immunotherapy Product Portfolio
- Figure 8.10: AstraZeneca PLC: Overall Financials, 2015-2017
- Figure 8.11: AstraZeneca PLC: Net Revenue (by Business Segment), 2015-2017
- Figure 8.12: AstraZeneca PLC: Revenue: Net Revenue (by Regions), 2015-2017
- Figure 8.13: AstraZeneca PLC: R&D Expenditure, 2015-2017
- Figure 8.14: AstraZeneca PLC: SWOT Analysis
- Figure 8.15: Bristol-Myers Squibb: Product Portfolio
- Figure 8.16: Bristol-Myers Squibb: Overall Financials
- Figure 8.17: Bristol-Myers Squibb: Net Revenue (by Regions), 2015-2017
- Figure 8.18: Bristol-Myers Squibb: R&D Expenditure, 2015-2017
- Figure 8.19: Bristol-Myers Squibb: SWOT Analysis
- Figure 8.20: Celgene Corporation: Overall Financials
- Figure 8.21: Celgene Corporation: Net Revenue (by Region), 2015-2017
- Figure 8.22: Celgene Corporation: R&D Expenditure, 2015-2017
- Figure 8.23: Celgene Corporation: SWOT Analysis
- Figure 8.24: DNATRIX Therapeutics: SWOT Analysis
- Figure 8.25: Eli Lilly and Company: Product Portfolio
- Figure 8.26: Eli Lilly and Company: Overall Financials, 2015-2017
- Figure 8.27: Eli Lilly and Company: Net Revenue (by Business Segments), 2015-2017
- Figure 8.28: Eli Lilly and Company: Net Revenue (by Regions), 2015-2017
- Figure 8.29: Eli Lilly and Company: Research and Development Expenditure, 2015-2017
- Figure 8.30: Eli Lilly and Company: SWOT Analysis
- Figure 8.31: Gilead Sciences, Inc.: Overall Financials
- Figure 8.32: Gilead Sciences, Inc.: Net Revenue (by Region), 2015-2017
- Figure 8.33: Gilead Sciences, Inc.: Research and Development Expenditure, 2015-2017
- Figure 8.34: Gilead Sciences, Inc.: SWOT Analysis
- Figure 8.35: Fate Therapeutics: Overall Financials
- Figure 8.36: Fate Therapeutics: Research and Development Expenditure, 2015-2017

- Figure 8.37: Fate Therapeutics: SWOT Analysis
- Figure 8.38: F. Hoffmann La Roche AG: Product Portfolio
- Figure 8.39: F. Hoffmann La Roche: Overall Financials
- Figure 8.40: F. Hoffmann La Roche: Net Revenue (by Business Segment), 2015-2017
- Figure 8.41: F. Hoffmann La Roche: Net Revenue (by Geographic Regions), 2015-2017
- Figure 8.42: F. Hoffmann La Roche: Research and Development Expense, 2015-2017
- Figure 8.43: F. Hoffmann La Roche: SWOT Analysis
- Figure 8.44: JOHNSON & JOHNSON: Overall Financials, 2015-2017
- Figure 8.45: JOHNSON & JOHNSON (by Business Segment), 2015-2017
- Figure 8.46: JOHNSON & JOHNSON (by Region), 2015-2017
- Figure 8.47: JOHNSON & JOHNSON: Research and Development Expense, 2015-2017
- Figure 8.48 JOHNSON & JOHNSON: SWOT ANALYSIS
- Figure 8.49: Merck & Co, Inc.: Product Portfolio
- Figure 8.50: Merck & Co, Inc.: Overall Financials
- Figure 8.51: Merck & Co, Inc. (by Business Segment), 2015-2017
- Figure 8.52: Merck & Co, Inc (by Geographic Regions), 2015-2017
- Figure 8.53: Merck & Co, Inc.: Research and Development Expense, 2015-2017
- Figure 8.54: Merck & Co, Inc.: SWOT Analysis
- Figure 8.55: Novartis AG: Cancer Immunotherapy Product Portfolio
- Figure 8.56: Novartis AG: Overall Financials (2015-2017)
- Figure 8.57: Novartis AG (by Business Segment), 2015-2017
- Figure 8.58 Novartis AG (by Geographic Region), 2015-2017
- Figure 8.59 Novartis AG: Research and Development Expenditure, 2015-2017
- Figure 8.60: Novartis AG: SWOT Analysis
- Figure 8.61: Pfizer, Inc.: Cancer Immunotherapy Product Portfolio
- Figure 8.62: Pfizer, Inc.: Overall Financials, 2015-2017
- Figure 8.63: Pfizer, Inc.: Net Revenue (by Business Segment), 2015-2017
- Figure 8.64: Pfizer, Inc.: Net Revenue (by Region), 2015-2017
- Figure 8.65: Pfizer, Inc.: Research and Development Expense, 2015-2017
- Figure 8.66: Pfizer, Inc.: SWOT Analysis
- Figure 8.67: Precision BioSciences, Inc.: SWOT Analysis
- Figure 9.1: Global Cancer Immunotherapy Market Segmentation
- Figure 9.2: Research Methodology
- Figure 9.3: Primary Research Sources
- Figure 9.4: Secondary Research Sources
- Figure 9.5: Key Data Points from Primary and Secondary Sources
- Figure 9.6: Data Triangulation
- Figure 9.7: Top-Down Approach: Global Cancer Immunotherapy Market

Figure 9.8: Bottom-up Approach: Global Cancer Immunotherapy Market

Figure 9.9: Assumptions and Limitations

I would like to order

Product name: Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and Forecast, 2018-2028

Product link: <https://marketpublishers.com/r/GBF785346260EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBF785346260EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

